Wenseng Pan

Wenseng Pan, Ph.D., is an associate in Morgan Lewis's Business and Finance Practice. Ms. Pan advises multinational pharmaceutical companies, biotech startups, specialty pharmas, and medical device companies in structuring and negotiating all phases of complex commercial transactions. Her practice covers early stage research collaboration, product and technology licensing, and global alliance formation for product development and commercialization, as well as asset acquisition and divesture, manufacturing, and supply agreements. As a former scientist and a registered U.S. patent attorney, Ms. Pan provides unique knowledge in resolving business and patent issues in commercial transactions relating to small molecular drugs, biologics, medical devices, protein- and antibody-related platform technologies, and drug-delivery technologies. Ms. Pan also has experience in mergers and acquisitions (M&A) and the aggregate value of the M&A transactions she has advised is above $10 billion. Prior to joining Morgan Lewis, Ms. Pan was a corporate associate at a leading global M&A law firm, focusing on public and private M&A, securities law practice, and corporate law counseling. Prior to that, Ms. Pan practiced with a leading international law firm in New York, concentrating on private equity investments and corporate financing. She also has worked with both state-owned enterprises and privately owned emerging companies in China and is a frequent speaker of licensing and collaboration practice and other cross-border transactions relating to the life sciences industry in Asia. Ms. Pan received her J.D. from Columbia University Law School in 1998, where she was a Stone Scholar. She received her Ph.D. in chemistry from Columbia University in 1995, where she was a recipient of the Pegram Award, and her B.S. in material science from Fudan University, China in 1989, where she was a recipient of the First Class Award.